Cargando…

Effects of Mineralocorticoid Receptor Antagonists in Early-Stage Heart Failure With Preserved Ejection Fraction

BACKGROUND: Hospitalization with a first episode of heart failure (HF) is a serious event associated with poor clinical outcomes in HF with preserved ejection fraction (HFpEF). Identification of HFpEF via detection of elevated left ventricular filling pressure at rest or during exercise may allow ea...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kagami, Kazuki, Obokata, Masaru, Harada, Tomonari, Saito, Yuki, Naito, Ayami, Sorimachi, Hidemi, Yuasa, Naoki, Kato, Toshimitsu, Wada, Naoki, Adachi, Takeshi, Ishii, Hideki
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2023
Materias:	Original Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10290949/ https://www.ncbi.nlm.nih.gov/pubmed/37377513 http://dx.doi.org/10.1016/j.cjco.2023.03.001

Ejemplares similares

Contributions of anemia to exercise intolerance in heart failure with preserved ejection fraction–An exercise stress echocardiographic study
por: Naito, Ayami, et al.
Publicado: (2023)

Diagnostic value of expired gas analysis in heart failure with preserved ejection fraction
por: Saito, Yuki, et al.
Publicado: (2023)

Diastolic Filling Time, Chronotropic Response, and Exercise Capacity in Heart Failure and Preserved Ejection Fraction With Sinus Rhythm
por: Kagami, Kazuki, et al.
Publicado: (2022)

Adiposity and clinical outcomes in East Asian patients with heart failure and preserved ejection fraction
por: Seki, Yuko, et al.
Publicado: (2022)

Exercise Stress Echocardiography in the Diagnostic Evaluation of Heart Failure with Preserved Ejection Fraction
por: Harada, Tomonari, et al.
Publicado: (2022)

The H(2)FPEF and HFA-PEFF algorithms for predicting exercise intolerance and abnormal hemodynamics in heart failure with preserved ejection fraction
por: Amanai, Shiro, et al.
Publicado: (2022)

Pathophysiological and diagnostic importance of fatty acid-binding protein 1 in heart failure with preserved ejection fraction
por: Harada, Tomonari, et al.
Publicado: (2021)

Pathophysiological role of fatty acid‐binding protein 4 in Asian patients with heart failure and preserved ejection fraction
por: Harada, Tomonari, et al.
Publicado: (2020)

Prognostic impact of elevated fatty acid‐binding protein 1 in patients with heart failure
por: Kagami, Kazuki, et al.
Publicado: (2021)

Right atrial pressure represents cumulative cardiac burden in heart failure with preserved ejection fraction
por: Nagata, Reika, et al.
Publicado: (2022)

Prognostic impact of mineralocorticoid receptor antagonist in patients with heart failure with preserved ejection fraction
por: Suzuki, Sho, et al.
Publicado: (2020)

Implication of Mineralocorticoid Receptor Antagonist Esaxerenone in Patients With Heart Failure With Preserved Ejection Fraction
por: Imamura, Teruhiko, et al.
Publicado: (2021)

The non-steroidal mineralocorticoid receptor antagonist finerenone and heart failure with preserved ejection fraction
por: Kintscher, Ulrich, et al.
Publicado: (2023)

Identification of Patients with Preclinical Heart Failure with preserved Ejection Fraction Using the H(2)FPEF Score
por: Koepp, Katlyn E., et al.
Publicado: (2022)

Unilateral Lung Congestion During Exercise in a Patient With a Single Pulmonary Vein Stenosis
por: Kato, Toshimitsu, et al.
Publicado: (2021)

Visual echocardiographic scoring system of the left ventricular filling pressure and outcomes of heart failure with preserved ejection fraction
por: Murayama, Michito, et al.
Publicado: (2021)

Effects of mineralocorticoid receptor antagonists in patients with preserved ejection fraction: a meta-analysis of randomized clinical trials
por: Chen, Yanmei, et al.
Publicado: (2015)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Kawanami, Daiji, et al.
Publicado: (2021)

Benefits of the Non-Steroidal Mineralocorticoid Receptor Antagonist Finerenone in Metabolic Syndrome-Related Heart Failure with Preserved Ejection Fraction
por: Lima-Posada, Ixchel, et al.
Publicado: (2023)

Pathophysiologic Contributions of Visceral Adiposity to Left Ventricular Diastolic Dysfunction
por: Nagata, Reika, et al.
Publicado: (2023)

Mineralocorticoid Receptor Antagonists, Blood Pressure, and Outcomes in Heart Failure With Reduced Ejection Fraction
por: Serenelli, Matteo, et al.
Publicado: (2020)

Steroidal and non-steroidal mineralocorticoid receptor antagonists in cardiorenal medicine
por: Agarwal, Rajiv, et al.
Publicado: (2020)

Effect of Mineralocorticoid Receptor Antagonists on Cardiac Structure and Function in Patients With Diastolic Dysfunction and Heart Failure With Preserved Ejection Fraction: A Meta‐Analysis and Systematic Review
por: Pandey, Ambarish, et al.
Publicado: (2015)

Effect of mineralocorticoid receptor antagonists on cardiac function in patients with heart failure and preserved ejection fraction: a systematic review and meta-analysis of randomized controlled trials
por: Kapelios, Chris J., et al.
Publicado: (2019)

Why are mineralocorticoid receptor antagonists cardioprotective?
por: Chai, Wenxia, et al.
Publicado: (2006)

Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
por: Benini, Annachiara, et al.
Publicado: (2022)

30 YEARS OF THE MINERALOCORTICOID RECEPTOR: Mineralocorticoid receptor antagonists: 60 years of research and development
por: Kolkhof, Peter, et al.
Publicado: (2017)

Correction: Incremental value of mineralocorticoid receptor antagonists in patients with heart failure with reduced ejection fraction treated with sacubitril/valsartan
Publicado: (2023)

The Ascent of Mineralocorticoid Receptor Antagonists in Diabetic  Nephropathy
por: Goenka, Luxitaa, et al.
Publicado: (2019)

Renoprotective Effect of the Mineralocorticoid Receptor Antagonist Esaxerenone
por: Oshima, Akira, et al.
Publicado: (2021)

Mineralocorticoid Receptor Antagonists in Diabetic Kidney Disease
por: Vodošek Hojs, Nina, et al.
Publicado: (2021)

Mineralocorticoid receptor antagonists in cardiovascular translational biology
por: Chilton, Robert J., et al.
Publicado: (2023)

The Pharmacokinetics of the Nonsteroidal Mineralocorticoid Receptor Antagonist Finerenone
por: Heinig, Roland, et al.
Publicado: (2023)

Mineralocorticoid Receptor-Associated Mechanisms in Diabetic Kidney Disease and Clinical Significance of Mineralocorticoid Receptor Antagonists
por: Mende, Christian W., et al.
Publicado: (2023)

Sex differences in left ventricular afterload and diastolic function are independent from the aortic size
por: Sorimachi, Hidemi, et al.
Publicado: (2019)

Mineralocorticoid receptor antagonists: emerging roles in cardiovascular medicine
por: Funder, John W
Publicado: (2013)

Oral mineralocorticoid antagonists for recalcitrant central serous chorioretinopathy
por: Chin, Eric K, et al.
Publicado: (2015)

Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists
por: Yugar-Toledo, Juan Carlos, et al.
Publicado: (2017)

Effects of mineralocorticoid receptor antagonists on the progression of diabetic nephropathy
por: Sun, Li‐Jing, et al.
Publicado: (2017)

Mineralocorticoid Receptor Antagonists—Use in Chronic Kidney Disease
por: Baran, Wiktoria, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_h02bfevg8cisqdpgfd7t98niou